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Abstract
Objective—To compare the rates of gestational diabetes (GDM) among women who received serial
doses of 17 alpha hydroxyprogesterone caproate (17-OHPC) versus placebo.
Study Design—Secondary analysis of two double-blind randomized placebo-controlled trials of
17-OHPC given to women at risk for preterm delivery. The incidence of GDM was compared between
women who received 17-OHPC or placebo.
Results—We included 1094 women; 441 had singleton and 653 had twin gestations. Combining
the two studies, 616 received 17-OHPC and 478 received placebo. Among singleton and twin
pregnancies, rates of GDM were similar in women receiving 17-OHPC versus placebo (5.8% vs.
4.7%, p= 0.64 and 7.4% vs 7.6%, p =0.94, respectively). In the multivariable model, progesterone
was not associated with GDM (adjusted odds ratio (adj OR) 1.04, 95% confidence interval (CI) 0.62
to 1.73).
Conclusion—Weekly administration of 17-OHPC is not associated with higher rates of gestational
diabetes in either singleton or twin pregnancies.
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INTRODUCTION
Preterm birth (PTB), defined as birth between 200/7 to 366/7 weeks gestation, remains a major
cause of neonatal morbidity and mortality worldwide. In the United States, the rate of PTB has
progressively increased from 9 percent to 12 percent over the past two decades.1 Public health
campaigns and medical interventions including trials of decreased maternal activity, home
uterine activity monitoring, tocolytic therapy, and antibiotic therapy targeted against various
organisms, have yet to produce an effective and consistent model for PTB prevention.2 The
use of progestins to prevent PTB has regained popularity after two randomized controlled trials
in 2003 showed a reduction in preterm birth among women at high risk for PTB.3,4 The
American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-
Fetal Medicine suggest offering progesterone to women with a singleton gestation and a prior
PTB and state that other indications for the use of this drug need further investigation.5
With increasing use of progestagens throughout pregnancy, there should be ongoing evaluation
of the potential impact of these medications on both mother and fetus. Throughout pregnancy,
metabolic changes occur to meet the needs of the growing fetus. Several essential pregnancy
hormones including progesterone, cortisol, human placental lactogen, and estrogen affect
insulin homeostasis and may influence the frequency of gestational diabetes (GDM).
Progesterone is thought to exhibit diabetogenic properties through a reduction in glucose
transporter 4 expressions or by impairing the normal β cell adaptive response of enhanced
insulin secretion.6 Animal studies have demonstrated that progesterone plays a key role in
pancreatic function and in signaling insulin release.7 These observations raise the question of
whether progesterone administration during pregnancy increases the risk of gestational
diabetes. 8
Gestational diabetes, affecting roughly 5% of women, is one of the most common diseases
during pregnancy and is associated with adverse perinatal outcomes.9 It is also thought to be
slightly more common in twin pregnancies, although data are conflicting.10 A recent cohort
study examining the association of treatment with 17 alpha hydroxyprogesterone caproate (17-
OHPC) with gestational diabetes in singleton pregnancies found a significantly higher rate of
gestational diabetes in women receiving 17-OHPC compared with patients with a prior PTB
who did not receive this intervention.8 Thus, our purpose was to evaluate the effect of
prophylactic 17-OHPC on the rate of GDM in both singleton and twin gestations.
MATERIALS AND METHODS
This is a secondary analysis of two randomized, double-blinded, placebo-controlled clinical
trials of 17-OHPC to prevent recurrent PTB in singleton pregnancies and to prevent PTB in
twin pregnancies. Full details of the methods and study design have been previously reported.
3,11 In the prevention of recurrent PTB trial, 463 women with at least one previous spontaneous
preterm delivery were randomized using a 2:1 randomization scheme to receive weekly
injections of 17-OHPC or placebo beginning at 16 to 206/7 weeks gestation and continuing
until 366/7 weeks gestation. In the prevention of PTB in twin pregnancies, 661 women were
randomized to receive weekly injections of 17-OHPC or placebo beginning at 16 to 206/7 weeks
gestation and continuing until delivery or 346/7 weeks gestation. Women from the singleton
trial with a pre-pregnancy diagnosis of diabetes (17 cases), unknown GDM status (1 case) or
who were lost to follow-up (4 cases) were excluded from this analysis, resulting in 293 and
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148 patients in the 17-OHPC and placebo groups, respectively. No women in the twin trial had
pre-existing diabetes as it was a trial exclusion. Women with GDM status unknown (2 cases)
or who were lost to follow-up (6 cases) were excluded from the analysis, leaving 323 and 330
patients in the 17-OHPC and placebo groups, respectively. Gestational ages for all participants
in both studies were confirmed by first or second trimester sonogram.
The outcome of interest in this analysis was the rate of gestational diabetes in singleton or twin
pregnancies in women who received 17-OHPC. The presence of gestational diabetes was based
upon documentation in the medical record. GDM was listed as either present or absent; results
of the glucose screen and 3 hour oral glucose tolerance test were not reviewed to verify the
diagnosis. Because this is a secondary analysis, criteria for diagnosis of GDM were not pre-
defined. However, the centers that participated in the original study use similar guidelines to
diagnose gestational diabetes. The association of patient characteristics and GDM were
evaluated using the Wilcoxon test, for continuous variables, and χ2 test for categorical
variables. The relationship between 17-OHPC and GDM was further investigated using a
multivariable logistic regression, controlling for variables that may influence the presence of
GDM including maternal age, body mass index (BMI)≥30, twin gestation, and African-
American race. Maternal age was evaluated as a continuous variable; the odds ratio for this
variable reflects the incremental risk of developing GDM per year of maternal age. Odds ratios
(OR) and 95% confidence intervals (CI) for GDM were determined. Nominal statistical
significance was set at a p-value less than 0.05.
RESULTS
In this analysis, 1094 women with known GDM status were included [Table 1]. Overall, the
rate of gestational diabetes was 5.4% in singleton pregnancies and 7.5% in twin pregnancies.
In the prevention of recurrent PTB trial in singleton pregnancies, the maternal demographic
characteristics between groups were similar except for number of prior preterm deliveries.
As shown in Figure 1, there was no difference in rates of GDM in women receiving 17-OHPC
versus placebo in either group (singletons, 5.8% vs. 4.7%, RR 1.23, 95% CI (0.52, 2.89),
p=0.64; twins 7.4% vs. 7.6%, RR 0.98, 95% CI (0.57, 1.68), p=0.94). Maternal age and body
mass index (BMI) were significantly associated with GDM (p < 0.001, and p <0.001,
respectively). The association between GDM and 17-OHPC use was assessed controlling for
maternal age, study type (singleton/twin) and prepregnancy BMI. Pregravid body mass index
of ≥30 mg/k2 (adjOR 3.52, 95% CI 2.07–5.99) was the strongest predictor of GDM [Table 2].
Use of 17-OHPC did not modify the risk of GDM (adjOR 1.04 95% CI 0.62–1.73). Because
screening for gestational diabetes is usually performed between 24 and 28 weeks, we also
analyzed the incidence of gestational diabetes for deliveries after 28 weeks of gestation in order
to capture the majority of diagnoses. We found that 17-OHPC was also not associated with
gestational diabetes if this diagnosis was made by 28 weeks (adjOR 1.00, 95% CI 0.61–1.67).
COMMENT
Our study shows that administration of 17-OHPC to both singleton and twin pregnancies did
not increase the rate of gestational diabetes. The rate of gestational diabetes in our study is
consistent with the current national estimate of 5%.12 Traditional risk factors such as maternal
BMI and age, rather, continued to be associated with an increased risk for GDM.
Historically, we have associated the hormonal changes associated with pregnancy, particularly
increasing levels of estrogen and progesterone, with insulin resistance. Picard and colleagues
have shown that progesterone accelerates the progression of gestational diabetes in a study
using progesterone receptor knock-out mice.7 They also showed that administration of an
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antagonist to the progesterone receptor, RU-486, reduced blood glucose levels. Recent data
suggest, however, that estrogen and progesterone are protective against insulin resistance.
Margolies et al. found that postmenopausal women on estrogen and progesterone were less
likely to develop diabetes than women not taking these hormones.13 Investigators have actually
sought to use these hormones to prevent the onset of insulin resistance in an animal model.14
Our results were different than those of Rebarber and colleagues.8 As in their study, our data
were also collected prospectively. The data gathered by the Maternal-Fetal Medicine Units are
collected by trained research staff on detailed data forms. Patients in both arms of the singleton
and twin studies were seen weekly by research staff with ongoing data collection. Because our
data were gathered as part of one of two randomized, double-blind, placebo-controlled trials,
the possibility of bias is greatly decreased. By design, an RCT results in 2 groups of patients
with similar characteristics, limiting the chance of selection bias, while the double-blinding
ensures that the provider and patient are unaware of the treatment assignment, limiting systemic
bias. Those receiving placebo were monitored as closely as those receiving study drug. The
study by Rebarber et al. was observational, therefore by design the possibility for selection
bias (which women received 17-OHPC) and ascertainment bias (which women were tested
and diagnosed for gestational diabetes) exists. It is unclear which co-morbidities allowed for
the controls to be entered into the Matria database since these patients were not receiving
placebo. It is also not clear whether the patient provider or the Matria staff collected the patient
data, and whether data were collected at regular time intervals bringing into question the data
ascertainment.
The limitations of this study warrant discussion. This is a secondary analysis of two separate
studies. The diagnosis of GDM was chart abstracted; information was not provided regarding
timing of GDM testing or criteria used for the diagnosis of GDM. Prior obstetrical information
including GDM in a previous pregnancy or history of macrosomia was also not included. While
we cannot ascertain how GDM was diagnosed, we do know that there is not a wide variation
in criteria used for this diagnosis amongst the centers involved in this study. Additionally, there
were some differences amongst the patients from either study. The most important difference
was the higher percent of African-Americans in the preterm birth prevention study compared
to the twin study since African-American race influences the development of GDM. However,
race was controlled for in the logistic regression model, and our findings remained consistent.
The strengths of this study are the large numbers of patients included for analysis. We included
two separate randomized controlled trials, yet they have similar results. Finally, as mentioned
previously, the RCT design limits our likelihood for selection and systemic bias.
We did not perform a post-hoc power analysis, as this practice is not deemed appropriate in
the setting of a fixed sample size, such as in the case of secondary analyses. Our point estimate
for the association of 17-OHPC with GDM of 1.04 along with our 95% confidence intervals
suggest that there was not an association between the two.
Progesterone has many recognized effects on the myometrium, including preventing formation
of gap junctions, decreasing oxytocin receptors, and decreasing conductance of contractions,
that may mediate the decrease in preterm birth in women at risk, but the exact mechanism of
action is unknown.15 Progesterone is also a recognized anti-inflammatory, which is why
investigators are now evaluating its use for women with a short cervix.16,17 ACOG has
cautioned that research should be performed before expanding the indication of this drug.5
Similarly, collecting data on the potential complications associated with its use, such as the
data on GDM collected in this study, should continue as the use of progesterone becomes
common practice.
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In conclusion weekly administration of 17-OHPC is not associated with higher rates of
gestational diabetes in either singleton or twin pregnancies. Women using progesterone during
pregnancy needn’t undergo glucose tolerance screening outside of standard testing unless
additional risk factors are present.
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Rates of GDM among Treatment and Placebo Patients
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Table 2
Maternal Characteristics, Study Group, Treatment and Risk for GDM
adjOR 95% CI
Maternal Age (yrs) 1.11 1.06–1.15
Obesity (BMI ≥30 kg/m2) 3.52 2.07–5.99
Twin Pregnancy 0.97 0.53–1.77
African–American Race 1.05 0.56–1.94
17-OHPC Use 1.04 0.62–1.73
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